

Appendix 5 Table 1

Percentage completeness for each predetermined data item - LUNG

| | PRE | | | | | | POST | | | | | | Proportion difference | |
|--|------|-----|-----|-------|--------------|------------|------|-----|-----|-------|--------------|------------|-----------------------|------------|
| | yes | no | n/a | total | total needed | % complete | yes | no | n/a | total | total needed | % complete | | 95% CI |
| Tumour morphology | 82 | 41 | 2 | 125 | 123 | 67% | 76 | 8 | 0 | 84 | 84 | 90% | 0.24 | 0.13-0.34 |
| Tumour location | 99 | 24 | 2 | 125 | 123 | 80% | 82 | 2 | 0 | 84 | 84 | 98% | 0.17 | 0.9-0.25 |
| Tumour dimensions | 114 | 9 | 2 | 125 | 123 | 93% | 80 | 0 | 4 | 84 | 80 | 100% | 0.07 | 0.02-0.13 |
| Differentiation from local consolidation | 68 | 27 | 30 | 125 | 95 | 72% | 22 | 10 | 52 | 84 | 32 | 69% | - 0.03 | -0.22-0.14 |
| Endobronchial disease | 69 | 50 | 6 | 125 | 119 | 58% | 78 | 6 | 0 | 84 | 84 | 93% | 0.35 | 0.24-0.45 |
| Tumour locally invades | 97 | 24 | 4 | 125 | 121 | 80% | 68 | 16 | 0 | 84 | 84 | 81% | 0.01 | -0.11-0.11 |
| Distal lung/lobe atelectasis | 70 | 51 | 4 | 125 | 121 | 58% | 69 | 14 | 1 | 84 | 83 | 83% | 0.25 | 0.13-0.36 |
| Regional lymph nodes | 117 | 8 | 0 | 125 | 125 | 94% | 84 | 0 | 0 | 84 | 84 | 100% | 0.06 | 0.01-0.12 |
| Metastatic disease - liver | 118 | 6 | 1 | 125 | 124 | 95% | 83 | 1 | 0 | 84 | 84 | 99% | 0.04 | -0.02-0.09 |
| Pulmonary nodules | 114 | 11 | 0 | 125 | 125 | 91% | 79 | 5 | 0 | 84 | 84 | 94% | 0.03 | -0.05-0.10 |
| Adrenal metastatic disease | 114 | 10 | 1 | 125 | 124 | 92% | 83 | 1 | 0 | 84 | 84 | 99% | 0.07 | 0.0-0.13 |
| Bone metastatic disease | 107 | 17 | 1 | 125 | 124 | 86% | 81 | 3 | 0 | 84 | 84 | 96% | 0.10 | 0.02-0.18 |
| Cerebral metastatic disease | 5 | 24 | 96 | 125 | 29 | 17% | 60 | 12 | 12 | 84 | 72 | 83% | 0.66 | 0.46-0.78 |
| Pleural disease | 86 | 39 | 0 | 125 | 125 | 69% | 82 | 2 | 0 | 84 | 84 | 98% | 0.29 | 0.19-0.38 |
| Pericardial effusion | 67 | 58 | 0 | 125 | 125 | 54% | 61 | 23 | 0 | 84 | 84 | 73% | 0.19 | 0.06-0.31 |
| Other sites of metastases | 101 | 17 | 7 | 125 | 118 | 86% | 66 | 18 | 0 | 84 | 84 | 79% | - 0.07 | -0.18-0.04 |
| Overall stage | 81 | 44 | 0 | 125 | 125 | 65% | 82 | 2 | 0 | 84 | 84 | 98% | 0.33 | 0.23-0.42 |
| Overall total | 1509 | 460 | 156 | 2125 | 1969 | 77% | 1236 | 123 | 69 | 1428 | 1359 | 91% | 0.14 | 0.12-0.17 |

Appendix 5 Table 2

Percentage completeness for each predetermined data item - PROSTATE

| | PRE | | | | | | POST | | | | | | Proportion difference | |
|--|-----|------|-----|-------|--------------|------------|------|-----|-----|-------|--------------|------------|-----------------------|------------|
| | yes | no | n/a | total | total needed | % complete | yes | no | n/a | total | total needed | % complete | % | 95% CI |
| Prostate gland dimensions/volume | 29 | 127 | 0 | 156 | 156 | 19% | 86 | 22 | 0 | 108 | 108 | 80% | 0.61 | 0.50-0.69 |
| BPH | 32 | 124 | 0 | 156 | 156 | 21% | 73 | 35 | 0 | 108 | 108 | 68% | 0.47 | 0.35-0.57 |
| Lesion location | 114 | 42 | 0 | 156 | 156 | 73% | 87 | 2 | 19 | 108 | 89 | 98% | 0.25 | 0.16-0.32 |
| Organ confined | 106 | 50 | 0 | 156 | 156 | 68% | 71 | 17 | 20 | 108 | 88 | 81% | 0.13 | 0.01-0.23 |
| Extending beyond prostate | 101 | 55 | 0 | 156 | 156 | 65% | 61 | 27 | 20 | 108 | 88 | 69% | 0.05 | -0.08-0.16 |
| Extending into seminal vesicles | 96 | 60 | 0 | 156 | 156 | 62% | 85 | 4 | 19 | 108 | 89 | 96% | 0.34 | 0.24-0.42 |
| Extending into bladder neck | 16 | 140 | 0 | 156 | 156 | 10% | 57 | 31 | 20 | 108 | 88 | 65% | 0.55 | 0.43-0.64 |
| Fixed or into adjacent organs or pelvic wall | 15 | 141 | 0 | 156 | 156 | 10% | 57 | 31 | 20 | 108 | 88 | 65% | 0.55 | 0.43-0.65 |
| Neurovascular bundle | 25 | 131 | 0 | 156 | 156 | 16% | 62 | 26 | 20 | 108 | 88 | 70% | 0.54 | 0.42-0.64 |
| Pelvic nodes | 146 | 10 | 0 | 156 | 156 | 94% | 105 | 3 | 0 | 108 | 108 | 97% | 0.04 | -0.02-0.09 |
| Nodes benign or malignant | 97 | 49 | 10 | 156 | 146 | 66% | 13 | 5 | 90 | 108 | 18 | 72% | 0.06 | -0.18-0.23 |
| Anatomic location if positive | 37 | 45 | 74 | 156 | 82 | 45% | 14 | 4 | 90 | 108 | 18 | 78% | 0.33 | 0.07-0.49 |
| TNM staging | 71 | 85 | 0 | 156 | 156 | 46% | 100 | 8 | 0 | 108 | 108 | 93% | 0.47 | 0.37-0.56 |
| Overall total | 885 | 1059 | 84 | 2028 | 1944 | 46% | 871 | 215 | 318 | 1404 | 1086 | 80% | 0.35 | 0.31-0.38 |

Appendix 5 Table 3

Percentage completeness for each predetermined data item - CERVICAL

| | PRE | | | | | | POST | | | | | | Proportion difference | |
|------------------------------|-----|-----|-----|-------|--------------|------------|------|-----|-----|-------|--------------|------------|-----------------------|------------|
| | yes | no | n/a | total | total needed | % complete | yes | no | n/a | total | total needed | % complete | | 95% CI |
| Tumour size | 70 | 17 | 30 | 117 | 87 | 80% | 29 | 2 | 15 | 46 | 31 | 94% | 0.13 | 0.03-0.24 |
| Tumour position | 44 | 43 | 30 | 117 | 87 | 51% | 29 | 2 | 15 | 46 | 31 | 94% | 0.43 | 0.25-0.54 |
| Morphology | 31 | 56 | 30 | 117 | 87 | 36% | 26 | 5 | 15 | 46 | 31 | 84% | 0.48 | 0.29-0.61 |
| Depth of invasion | 68 | 49 | 0 | 117 | 117 | 58% | 27 | 4 | 15 | 46 | 31 | 87% | 0.29 | 0.11-0.41 |
| Vaginal involvement | 53 | 64 | 0 | 117 | 117 | 45% | 44 | 2 | 0 | 46 | 46 | 96% | 0.50 | 0.37-0.60 |
| Pelvic side wall involvement | 33 | 84 | 0 | 117 | 117 | 28% | 45 | 1 | 0 | 46 | 46 | 98% | 0.70 | 0.60-0.77 |
| Hydronephrosis | 66 | 51 | 0 | 117 | 117 | 56% | 30 | 16 | 0 | 46 | 46 | 65% | 0.09 | -0.08-0.24 |
| Bladder involvement | 43 | 74 | 0 | 117 | 117 | 37% | 46 | 0 | 0 | 46 | 46 | 100% | 0.63 | 0.51-0.71 |
| Rectum involvement | 38 | 79 | 0 | 117 | 117 | 32% | 46 | 0 | 0 | 46 | 46 | 100% | 0.68 | 0.56-0.75 |
| Ascites | 34 | 83 | 0 | 117 | 117 | 29% | 33 | 13 | 0 | 46 | 46 | 72% | 0.43 | 0.26-0.56 |
| Pelvic nodes | 111 | 6 | 0 | 117 | 117 | 95% | 45 | 1 | 0 | 46 | 46 | 98% | 0.03 | -0.07-0.09 |
| Para-aortic nodes | 93 | 24 | 0 | 117 | 117 | 79% | 39 | 7 | 0 | 46 | 46 | 85% | 0.05 | -0.09-0.17 |
| Endometrium | 39 | 78 | 0 | 117 | 117 | 33% | 30 | 16 | 0 | 46 | 46 | 65% | 0.32 | 0.13-0.46 |
| Myometrium | 45 | 72 | 0 | 117 | 117 | 38% | 29 | 17 | 0 | 46 | 46 | 63% | 0.25 | 0.08-0.40 |
| Right & left adnexae | 74 | 43 | 0 | 117 | 117 | 63% | 33 | 13 | 0 | 46 | 46 | 72% | 0.08 | -0.08-0.23 |
| FIGO stage | 63 | 43 | 11 | 117 | 106 | 59% | 34 | 10 | 2 | 46 | 44 | 77% | 0.18 | 0.01-0.32 |
| iTNM stage | 13 | 93 | 11 | 117 | 106 | 12% | 31 | 15 | 0 | 46 | 46 | 67% | 0.55 | 0.39-0.68 |
| Overall total | 918 | 959 | 112 | 1989 | 1877 | 49% | 596 | 124 | 62 | 782 | 720 | 83% | 0.34 | 0.30-0.37 |

Appendix 5 Table 4

Percentage completeness for each predetermined data item - ENDOMETRIAL

| | PRE | | | | | | POST | | | | | | Proportion difference | |
|------------------------------|-----|------|-----|-------|--------------|------------|------|-----|-----|-------|--------------|------------|-----------------------|------------|
| | yes | no | n/a | total | total needed | % complete | yes | no | n/a | total | total needed | % complete | | 95% CI |
| Size of uterus | 48 | 64 | 0 | 112 | 112 | 43% | 59 | 0 | 0 | 59 | 59 | 100% | 0.57 | 0.46-0.66 |
| Endometrial thickness | 31 | 81 | 0 | 112 | 112 | 28% | 56 | 2 | 1 | 59 | 58 | 97% | 0.69 | 0.57-0.77 |
| Tumour dimensions | 55 | 53 | 4 | 112 | 108 | 51% | 57 | 0 | 2 | 59 | 57 | 100% | 0.49 | 0.38-0.58 |
| Depth of myometrial invasion | 84 | 25 | 3 | 112 | 109 | 77% | 59 | 0 | 0 | 59 | 59 | 100% | 0.23 | 0.14-0.32 |
| Benign myometrial pathology | 28 | 84 | 0 | 112 | 112 | 25% | 35 | 24 | 0 | 59 | 59 | 59% | 0.34 | 0.19-0.48 |
| Uterine serosal involvement | 29 | 83 | 0 | 112 | 112 | 26% | 57 | 2 | 0 | 59 | 59 | 97% | 0.71 | 0.59-0.78 |
| Cervix | 64 | 48 | 0 | 112 | 112 | 57% | 59 | 0 | 0 | 59 | 59 | 100% | 0.43 | 0.32-0.52 |
| Ovarian involvement | 75 | 37 | 0 | 112 | 112 | 67% | 55 | 4 | 0 | 59 | 59 | 93% | 0.26 | 0.14-0.36 |
| Peritoneal involvement | 23 | 89 | 0 | 112 | 112 | 21% | 34 | 25 | 0 | 59 | 59 | 58% | 0.37 | 0.22-0.50 |
| Vaginal involvement | 9 | 103 | 0 | 112 | 112 | 8% | 59 | 0 | 0 | 59 | 59 | 100% | 0.92 | 0.83-0.96 |
| Bladder involvement | 8 | 104 | 0 | 112 | 112 | 7% | 59 | 0 | 0 | 59 | 59 | 100% | 0.93 | 0.84-0.96 |
| Rectum involvement | 4 | 108 | 0 | 112 | 112 | 4% | 59 | 0 | 0 | 59 | 59 | 100% | 0.96 | 0.88-0.99 |
| Hydronephrosis | 29 | 83 | 0 | 112 | 112 | 26% | 33 | 26 | 0 | 59 | 59 | 56% | 0.30 | 0.15-0.44 |
| Ascites | 48 | 64 | 0 | 112 | 112 | 43% | 34 | 25 | 0 | 59 | 59 | 58% | 0.15 | -0.01-0.29 |
| Pelvic nodes | 107 | 5 | 0 | 112 | 112 | 96% | 59 | 0 | 0 | 59 | 59 | 100% | 0.04 | -0.02-0.10 |
| Para-aortic nodes | 85 | 25 | 2 | 112 | 110 | 77% | 58 | 1 | 0 | 59 | 59 | 98% | 0.21 | 0.11-0.30 |
| FIGO stage | 82 | 29 | 1 | 112 | 111 | 74% | 58 | 1 | 0 | 59 | 59 | 98% | 0.24 | 0.14-0.33 |
| iTNM stage | 14 | 97 | 1 | 112 | 111 | 13% | 31 | 28 | 0 | 59 | 59 | 53% | 0.40 | 0.25-0.53 |
| Overall total | 823 | 1182 | 11 | 2016 | 2005 | 41% | 921 | 138 | 3 | 1062 | 1059 | 87% | 0.46 | 0.43-0.49 |

Appendix 5 Table 5

Percentage completeness for each predetermined data item - COLON

| | PRE | | | | | | POST | | | | | | Proportion difference | |
|---------------------------------|-----|------|-----|-------|--------------|------------|------|----|-----|-------|--------------|------------|-----------------------|------------|
| | yes | no | n/a | total | total needed | % complete | yes | no | n/a | total | total needed | % complete | | 95% CI |
| Location in colon | 124 | 16 | 2 | 142 | 140 | 89% | 85 | 1 | 2 | 88 | 86 | 99% | 0.10 | 0.04-0.17 |
| Advancing edge tumour | 5 | 124 | 13 | 142 | 129 | 4% | 83 | 2 | 3 | 88 | 85 | 98% | 0.94 | 0.86-0.97 |
| Bowel wall confined or not | 59 | 71 | 12 | 142 | 130 | 45% | 83 | 3 | 2 | 88 | 86 | 97% | 0.51 | 0.41-0.60 |
| Peritoneal infiltration | 15 | 115 | 12 | 142 | 130 | 12% | 80 | 7 | 1 | 88 | 87 | 92% | 0.80 | 0.70-0.86 |
| Tumour extension distance | 33 | 96 | 13 | 142 | 129 | 26% | 62 | 24 | 2 | 88 | 86 | 72% | 0.47 | 0.33-0.57 |
| Tumour diameter/thickness | 19 | 112 | 11 | 142 | 131 | 15% | 68 | 18 | 2 | 88 | 86 | 79% | 0.65 | 0.52-0.73 |
| Peritoneal disease | 13 | 129 | 0 | 142 | 142 | 9% | 83 | 5 | 0 | 88 | 88 | 94% | 0.85 | 0.76-0.90 |
| Retroperitoneal lymphadenopathy | 87 | 55 | 0 | 142 | 142 | 61% | 85 | 3 | 0 | 88 | 88 | 97% | 0.35 | 0.26-0.44 |
| Metastatic disease in liver | 134 | 8 | 0 | 142 | 142 | 94% | 87 | 1 | 0 | 88 | 88 | 99% | 0.04 | -0.01-0.10 |
| Pulmonary metastatic disease | 123 | 13 | 6 | 142 | 136 | 90% | 84 | 4 | 0 | 88 | 88 | 95% | 0.05 | -0.03-0.12 |
| T substage & N stage | 37 | 103 | 2 | 142 | 140 | 26% | 88 | 0 | 0 | 88 | 88 | 100% | 0.74 | 0.65-0.80 |
| Resectable irresectable | 0 | 142 | 0 | 142 | 142 | 0% | 73 | 15 | 0 | 88 | 88 | 83% | 0.83 | 0.73-0.89 |
| M0/M1 | 58 | 84 | 0 | 142 | 142 | 41% | 88 | 0 | 0 | 88 | 88 | 100% | 0.59 | 0.50-0.67 |
| Overall total | 707 | 1068 | 71 | 1846 | 1775 | 40% | 1049 | 83 | 12 | 1144 | 1132 | 93% | 0.53 | 0.50-0.55 |

Appendix 5 Table 6

Percentage completeness for each predetermined data item - RECTAL

| | PRE | | | | | | POST | | | | | | Proportion difference | |
|---|-----|------|-----|-------|--------------|------------|------|-----|-----|-------|--------------|------------|-----------------------|------------|
| | yes | no | n/a | total | total needed | % complete | yes | no | n/a | total | total needed | % complete | | 95% CI |
| Tumour morphology stated | 51 | 83 | 1 | 135 | 134 | 38% | 108 | 1 | 2 | 111 | 109 | 99% | 0.61 | 0.52-0.69 |
| Height from anal verge | 79 | 56 | 0 | 135 | 135 | 59% | 109 | 0 | 2 | 111 | 109 | 100% | 0.41 | 0.33-0.50 |
| Distal edge to PR sling | 31 | 104 | 0 | 135 | 135 | 23% | 102 | 7 | 2 | 111 | 109 | 94% | 0.71 | 0.61-0.78 |
| Muscularis propria breached | 123 | 12 | 0 | 135 | 135 | 91% | 104 | 6 | 1 | 111 | 110 | 95% | 0.03 | -0.04-0.10 |
| Extramural spread depth given | 34 | 81 | 20 | 135 | 115 | 30% | 86 | 23 | 2 | 111 | 109 | 79% | 0.49 | 0.37-0.59 |
| T sub stage | 64 | 70 | 1 | 135 | 134 | 48% | 96 | 15 | 0 | 111 | 111 | 86% | 0.39 | 0.27-0.48 |
| Description low rectal tumours | 19 | 45 | 71 | 135 | 64 | 30% | 15 | 14 | 82 | 111 | 29 | 52% | 0.22 | 0.09-0.42 |
| Extramural invasion | 45 | 90 | 0 | 135 | 135 | 33% | 102 | 8 | 1 | 111 | 110 | 93% | 0.59 | 0.49-0.68 |
| Site of closest CRM | 46 | 77 | 12 | 135 | 123 | 37% | 79 | 29 | 3 | 111 | 108 | 73% | 0.36 | 0.23-0.47 |
| Tumour distance to CRM | 30 | 91 | 14 | 135 | 121 | 25% | 65 | 40 | 6 | 111 | 105 | 62% | 0.37 | 0.24-0.48 |
| Peritoneal deposits | 5 | 127 | 3 | 135 | 132 | 4% | 92 | 19 | 0 | 111 | 111 | 83% | 0.79 | 0.70-0.85 |
| Pelvic side wall lymph nodes stated and characterised | 46 | 88 | 1 | 135 | 134 | 34% | 107 | 4 | 0 | 111 | 111 | 96% | 0.62 | 0.52-0.70 |
| T substage N stage | 80 | 55 | 0 | 135 | 135 | 59% | 109 | 2 | 0 | 111 | 111 | 98% | 0.39 | 0.30-0.47 |
| CRM clear/involved | 56 | 77 | 2 | 135 | 133 | 42% | 98 | 13 | 0 | 111 | 111 | 88% | 0.46 | 0.35-0.56 |
| EMVI positive/negative | 35 | 100 | 0 | 135 | 135 | 26% | 98 | 13 | 0 | 111 | 111 | 88% | 0.62 | 0.51-0.71 |
| Overall total | 744 | 1156 | 125 | 2025 | 1900 | 39% | 1370 | 194 | 101 | 1665 | 1564 | 88% | 0.48 | 0.46-0.51 |